Latest Breaking News On - Jacob stephen thomas - Page 1 : comparemela.com

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeSan diegoCostantine albanyMatthew taylorVineet kwatraJennifer eva selfridgeJacob stephen thomasInderjit mehmiBruce mackleKartik aysolaJudith llorin sangalangRichard waldronOmid hamidAmerican society of clinical oncologyBioatla inc

Abstract 1574238: Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety and Immune Activation in Adults with Refractory Sarcomas (NCT 03058289) -November 02, 2023 at 10:37 am EDT

Abstract 1574238: INTRATUMORAL INT230-6 ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH.

United statesNew yorkFox chase cancer centerAnthonyb el khoueiryAnthonyj olszanskiIanb waltersLos angelesLillianl siuDianal hannaChristian frederick meyerMatthew inghamJacob stephen thomasAlbiruni ryan abdul razakLewish benderLuish camachoNilofer saba azaz

Intensity Therapeutics Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in November

/PRNewswire/ Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.

United statesBritish columbiaEdna kaplanMerck sharpe dohmeAngel arnaoutJacob stephen thomasMichael millerBristol myers squibbMatthew inghamDevelopment agreementOntario institute of cancer researchOttawa hospital research instituteNational cancer instituteSociety for immunotherapy of cancerExhibition centerBristol myers squibb company

Intensity Therapeutics INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers

Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors Patients Receiving a Dose.

United statesEdna kaplanMerck sharpe dohmeLewish benderJacob stephen thomasMichael millerBristol myers squibbJacobs thomasDevelopment agreementOntario institute of cancer researchOttawa hospital research instituteCompany on twitterAmerican society of clinical oncologyNational cancer institutePrnewswire intensity therapeutics incIntensity therapeutics inc

CORRECTING and REPLACING -- Affimed N V

In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have.

United statesNew yorkBaden wübergJennifer rubelAndres cervantesElena garraldaGabriele hintzenAlexander fudukidisAmin alousiMichael emigNeeraj sainiKarenza alexisIndreshpal kaurRafet basarJeremy ramdialPilar nava parada